Conference Coverage: ASCO 2022 – Focus on Lung Cancer
Expert perspectives and strategic insights on the latest therapeutic developments and translational research in lung cancer treatment
June 13, 2022
Faculty Chair
Corey J. Langer, MD, FACP
University of Pennsylvania, Philadelphia, PA, USA
FACULTY MEMBERS
Solange Peters, MD, PhD
University of Lausanne, Switzerland
Roy Herbst, MD, PhD
Yale Cancer Center, New Haven, CT, USA
Enriqueta Felip, MD, PhD
Vall d’Hebron University Hospital, Barcelona, Spain
David Spigel, MD
Sarah Cannon Cancer Institute, Nashville, TN, USA
Mark Socinski, MD
AdventHealth Cancer Institute, Orlando, FL, USA
Paul Paik, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Lynette Sholl, MD
Dana-Farber Cancer Institute, Boston, MA, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Immunotherapy in Stage I–III NSCLC
- Immunotherapy in Stage IV NSCLC
- EGFR (common mutations): Resectable and Metastatic
- EGFR (exon 20 and other uncommon mutations)
- Oncogenic Fusions
- Oncogenic Mutations
- Other Targets in NSCLC/SCLC
